Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

San Francisco mayor hopes to woo biotech to fill office vacancies

By Brian Buntz | February 16, 2023

London Breed

London Breed [Image courtesy of Wikimedia Commons]

San Francisco Mayor London Breed has suggested that vacant downtown office spaces should be made available for biotech companies to expand, according to the San Francisco Business Times. The biotech industry could help breathe new life into the area, Breed argued.

She highlighted a 5% life sciences vacancy rate in the city in contrast to the 25% office vacancy rate. For context, the vacancy rate for the office market was about 5% before the pandemic.

Breen recently announced a 75,000-square-foot expansion of the Gladstone Institutes’ facility in Mission Bay. The organization is a non-profit biomedical research institution.

She proposed removing code barriers to help developers convert office space into biotech labs, saying that the city wants to make it easier so that it happens more quickly. Breed said that biotech is the future of San Francisco, and the city will work to make it easier to expand and transform other spaces in the city to be used for the same purpose.

Remote working has had a severe impact on San Francisco, ramping up office vacancies to new heights.

San Francisco had been one of the leading tech hubs in the U.S., but the tech industry has embraced the trend of remote work, contributing to the city’s vacancy rates.

Nearly two decades ago, San Francisco established Mission Bay as a biotech district, deliberately designed to avoid restrictive zoning and concerns from nearby residents. The first building in the area was Genentech Hall in 2002. A Gladstone facility followed in December 2004.

Now, Mission Bay is currently the most in-demand market in the city. The neighborhood has about a quarter of all office space available in the city.

Nearby South San Francisco has a long history in the biotech industry. The birthplace of Genentech is now seeing significant pipeline projects take shape. The city continues to be the nexus for the Bay Area’s lab development. Last fall, pharma giant Eli Lilly announced that it planned to lease a considerable amount of space in the city.


Filed Under: Biologics
Tagged With: biotech, San Francisco
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Avoiding aggregates: How new technology is helping mAb developers monitor a vital CQA
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years
Lumen Bioscience
How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE